Osteotech gets $14.5 million damages:
This article was originally published in Clinica
Osteotech has been awarded damages of $17.5 million in connection with its patent lawsuit against GenSci Regeneration Sciences and its subsidiary GenSci OrthoBiologics. The amount will be reduced by the $3 million that had previously been paid by DePuy AcroMed in settling Osteotech's claims against DePuy in this suit. Last month, the jury determined that two US patents of Osteotech were valid and that GenSci infringed both through its sale of DynaGraft gel and putty products. The court was due to hear arguments on Eatontown, New Jersey-based Osteotech's motion for a permanent injunction and GenSci's motion to stay the injunction pending an appeal.